Ipsen tosses CEO over 'strategic differences'; Lundbeck buys rights to Merck bipolar med;

 @FiercePharma: Sanofi cuts 1,700 U.S. jobs. Article | Follow @FiercePharma

Special Report: FDA's Top 10 Blockbuster Decisions. Report

> French pharmaceutical company Ipsen said it was ditching CEO Jean-Luc Bélingard, citing "strategic differences" over the group's development; he'll be replaced by Marc de Garidel, 52, formerly an Amgen vice president. Ipsen release | Report

> H. Lundbeck, the Danish drugmaker looking for replacements for its blockbuster antidepressant Lexapro, agreed to buy the rights to sell Merck's bipolar disorder treatment Sycrest. Lundbeck release | Report

> An arm of Citigroup and two other investors are mulling a sale of copycat drugmaker Biofarma, people familiar with the matter said, in what could be Turkey's biggest healthcare deal. Item

> Eli Lilly has sued Dr Reddy's Laboratories for infringing the patent on its cancer drug Gemzar. Report

> Despite its recent withdrawal from the market, the weight-loss drug Meridia (sibutramine) is likely to remain available through weight-loss nutritional supplements containing undeclared prescription-strength ingredients and other contaminants. News

> GlaxoSmithKline is to put British university students to work to discover the drugs of the future in a training program that will tap into the skills of the next generation of chemists at minimal cost. Report

> Taking folic acid supplements for five years seems to have no significant benefit for the prevention of cardiovascular disease or cancer, according to a meta-analysis. Article

 

Biotech News

 @FierceBiotech: Jazz shares hit sour note as FDA rejects fibromyalgia drug. Article | Follow @FierceBiotech

 @JohnCFierce: Once heard Peter Drucker talk about U.S. tech revolutions. 1st years: Disaster, as everyone piles into the hype. 2nd 10 years: Revolution.|  Follow @JohnCFierce

> History or hype? World's first ESC trial gets under way. News

> Halozyme chops preclinical ops in restructuring. Story

> Pfizer embraces pain pipeline in $3.6B King buyout. Article

> Euro-US hybrid Synosia lands $745M Parkinson's pact with UCB. Story

> Pfizer lung cancer drug looks promising in mid-stage study. Article

Biotech Research News

> Gelesis makes anti-obesity progress. Story

> Should human genes be patented? Item

> Scientists, lawyer 'unzip' their DNA for the world. News

> U.K. company develops weapon against hospital 'superbug'. Article

> Stem cell research in the embryonic stage. Report

> So you want to lead an innovative company? Respect the innovators. Story

Manufacturing News

> Hijacking, break-in mark recent cargo heists. Story

> FDA offers formatted data on recalls. Report

> Caraco tallies timing of consent decree fixes. Item

> Lipitor recall shares pallets, Puerto Rico with Tylenol, Glumetza. Article

> HHS takes both sides of egg bet for vax-making. Report

> India foresees spread of generics seizures via ACTA. News

 

And Finally... Urinary tract infections, pneumonia and other common ailments caused by germs that carry a new gene with the power to destroy antibiotics are intensifying fears of a fresh generation of so-called superbugs. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.